Pharmafile Logo

compulsory licence

- PMLiVE

ASCO: Amgen says viral therapy for melanoma “encouraging”

T-VEC is potential advancement in skin cancer treatment

EU flag

Nine pharma firms face EU fines over pay-for-delay deals

Lundbeck could be the hardest hit with a maximum penalty of €240m

- PMLiVE

ASCO: Merck and BMS trumpet melanoma trials

Positive study results for anti-PD-1 candidates lambrolizumab and nivolumab

Sanofi reception

Sanofi gives up on iniparib and otamixaban

Drops cancer drug and anticoagulant after negative late-stage trials

- PMLiVE

Merck KGaA to research cancer drug with Chinese biotech

German pharma firm teams up with BeiGene on BRAF inhibitor

- PMLiVE

FDA clears two GSK melanoma drugs

Tafinlar and Mekinist approved in the US along with companion diagnostic

National Institute for Health and Care Excellence NICE logo

NICE reverses negative guidance for Forxiga in diabetes

Final draft guidance backs the use of BMS/AstraZeneca’s SGLT-2 inhibitor in certain patients

- PMLiVE

US FDA approves Roche’s assay as first blood test to diagnose diabetes

Will help catch diabetes early in country where seven million people are undiagnosed

- PMLiVE

VCCP Health wins Mundipharma’s new product launch business

Agency hired to drive new product launches across Europe

- PMLiVE

India puts cost controls on medicines

Drugs (Prices Control) Order 2013 reduces price of hundreds of drugs

Payer focus in the personalised world of oncology and orphan diseases

Personalised medicine is transforming disease understanding and many traditional diagnoses may be fundamentally revised based on the new scientific understanding

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links